

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BAENTELI ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/003521

FILED: 4 APRIL 2005

U.S. APPLICATION NO: 10/594,412

35 USC §371 DATE:

FOR: USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE
TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-
PURINE-2,6-DIAMINE DERIVATIVES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the outstanding restriction requirement mailed 27 February 2009, a response to which is due 27 July 2009 with the attached extension of time request, applicants hereby elect prosecution of Group II without traverse, drawn to compounds of formula (I), comprising claims 4-8, 13-14, and 16. Applicants further elect species relating to the compound N*2*-Benzothiazol-6-yl-N*6*-tert-butyl-8-methyl-9H-purine-2,6-diamine.

The application is now in condition for examination and passage to allowance. Should the Examiner have any questions, please contact the undersigned.

Respectfully submitted,



Mark E. Baron
Attorney for Applicants
Reg. No. 46,150

Novartis Institutes for Biomedical Research
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-7347
Date: July 27, 2009